Literature DB >> 3979691

Continuous subcutaneous insulin infusion does not induce a significant acute phase response of serum amyloid A protein.

J J Bending, J C Pickup, I F Rowe, R Gallimore, G Tennent, H Keen, M B Pepys.   

Abstract

In a study of 23 matched pairs of Type 1 (insulin-dependent) diabetic patients receiving continuous subcutaneous insulin infusion or conventional insulin injection therapy respectively, there were no significant differences in serum levels of the acute phase proteins, serum amyloid A and C-reactive protein. These results do not support the suggestion that continuous subcutaneous insulin infusion stimulates serum amyloid A production or that it carries a risk of inducing reactive systemic amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3979691     DOI: 10.1007/bf00279927

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

1.  Reference method for the erythrocyte sedimentation rate (ESR) test on human blood.

Authors: 
Journal:  Br J Haematol       Date:  1973-05       Impact factor: 6.998

2.  ABC of diabetes. Continuous subcutaneous insulin infusion.

Authors:  J C Pickup
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-03

3.  Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis.

Authors:  E A Fagan; R F Dyck; P N Maton; H J Hodgson; V S Chadwick; A Petrie; M B Pepys
Journal:  Eur J Clin Invest       Date:  1982-08       Impact factor: 4.686

4.  Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis.

Authors:  F C De Beer; R K Mallya; E A Fagan; J G Lanham; G R Hughes; M B Pepys
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

5.  Association of insulin pump therapy with raised serum amyloid A in type I diabetes mellitus.

Authors:  M Brownlee; H Vlassara; A Cerami; T R Martin; J J Li; K P McAdam
Journal:  Lancet       Date:  1984-02-25       Impact factor: 79.321

6.  Unanticipated amyloidosis in dogs infused with insulin.

Authors:  A M Albisser; K P McAdam; K Perlman; S Carson; A Bahoric; J R Williamson
Journal:  Diabetes       Date:  1983-12       Impact factor: 9.461

7.  Solid-phase immunoradiometric assay for serum amyloid A protein using magnetisable cellulose particles.

Authors:  F C De Beer; R F Dyck; M B Pepys
Journal:  J Immunol Methods       Date:  1982-10-29       Impact factor: 2.303

8.  No evidence of amyloidosis in type I diabetics treated with continuous subcutaneous insulin infusion.

Authors:  V A Koivisto; A M Teppo; C P Maury; M R Taskinen
Journal:  Diabetes       Date:  1983-01       Impact factor: 9.461

9.  Failure to find amyloidosis in dogs treated with long-term intravenous insulin delivered by a totally implantable pump.

Authors:  S M Mauer; H Buchwald; T J Groppoli; T D Rohde; B D Wigness; W M Rupp; M W Steffes
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

10.  Quantitative radial immunodiffusion assay for serum amyloid A protein.

Authors:  R E Chambers; J T Whicher
Journal:  J Immunol Methods       Date:  1983-04-15       Impact factor: 2.303

  10 in total
  1 in total

Review 1.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.